<![CDATA[Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines]]>
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for pirtobrutinib (Jaypirca), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adults with chronic …